Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Drugs. 2023 May;83(7):639-643. doi: 10.1007/s40265-023-01865-w.
Keverprazan hydrochloride () is a potassium ion competitive acid blocker that is being developed by Jiangsu Carephar Pharmaceuticals for the treatment of acid-related disease. Keverprazan hydrochloride was recently approved in China for the treatment of adults with reflux oesophagitis or duodenal ulcer. This article summarizes the milestones in the development of keverprazan hydrochloride leading to this first approval for reflux oesophagitis and duodenal ulcer.
盐酸凯普拉嗪（）是一种钾离子竞争性酸阻滞剂，由江苏奥赛康药业开发，用于治疗与酸相关的疾病。盐酸凯普拉嗪最近在中国获批用于治疗成人反流性食管炎或十二指肠溃疡。本文总结了盐酸凯普拉嗪开发过程中的重要里程碑，最终使其首次获批用于反流性食管炎和十二指肠溃疡的治疗。
